In addition, the administration of U3-1402 alone or in combination with an EGFR-TKI was shown to significantly suppress the growth of EGFR-TKI-resistant NSCLC xenograft tumors (Yonesaka et al., 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.